stella
beta
A Study to Evaluate Safety, Tolerability, and Efficacy of AB-1009 Gene Therapy (GAA Gene) in Adult Participants With Late Onset Pompe Disease (PROGRESS-GT LOPD) — Stella
Recruiting
Back to Pompe Disease (Late-onset) trials
Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations
(10 sites)
United States
Barrow Neurological Institute, Phoenix, Arizona
University of California, Irvine (UCI), Irvine, California
Stanford Neuroscience Health Center, Palo Alto, California
NYU Langone, New York, New York
Duke University, Durham, North Carolina
Show all 10 locations
View full record on ClinicalTrials.gov